Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Gynecologic Oncology
•
Medical Oncology
•
Survivorship
•
Genetics
•
Breast Cancer, Non-metastatic
•
Sexual Health
•
Primary Care
Would you consider HRT after risk-reducing salpingo-oophorectomy for a young (mid-30s) patient with BRCA1 and a history of TNBC?
Related Questions
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?
How do you assess and counsel women with chronic post-lumpectomy or mastectomy pain?
Do you recommend self-breast exams to your patients with history of breast cancer in addition to imaging surveillance?
Do you follow LFTs in patients on tamoxifen as suggested in the prescribing guidelines?
Do you check AMH levels to decide on adjuvant chemotherapy in premenopausal patients with node-positive ER+ breast cancer?
Is there any definitive contraindication to use tamoxifen in patients with a brain aneurysm that is being monitored?
What neoadjuvant chemotherapy do you suggest for a rapidly growing triple-negative breast cancer?
Would you offer adjuvant chemotherapy for triple negative invasive papillary carcinoma of breast?
Would you offer adjuvant AC + pembrolizumab for a triple negative breast cancer patient whose tumor progressed on carboplatin + paclitaxel + pembrolizumab on KEYNOTE-522 and required urgent surgery (ypT3 ypN0)?
How do you approach early-stage breast cancer patients who are asking for ctDNA or tumor marker surveillance (or previously receiving these with another provider) when these are not part of the NCCN or ASCO guidelines?
